AKT1 and hepatocellular carcinoma: Some of the key concerns are that inhibitors of pPI3K/pAkt increase liver and inflammation as well as the risk of hepatic cancer because hepatic elimination from Akt contributes to chronic liver damage, inflammation and hepatocellular carcinoma (HCC) [22].